Full Press Release Details
NATICK, Mass. , July 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and only 16-contact percutaneous lead for spinal cord stimulation (SCS) therapy, and the Clik™ Anchor, an innovative locking system designed to secure and reduce unwanted migration of SCS leads. The research was presented at the International Spine Intervention Society (ISIS) 20th Annual Scientific Meeting in Las Vegas .
"Chronic pain affects the daily lives of more than 100 million Americans each year, and tens of thousands of patients with chronic pain have found that SCS systems help them manage their pain," said Maulik Nanavaty , senior vice president and president of the Neuromodulation Division at Boston Scientific. "The Infinion 16 Lead and Clik Anchor studies underscore our commitment to developing industry-leading technologies that advance the management of chronic pain and mitigate difficulties associated with SCS therapy."
Initial Spinal Cord Stimulation Trial Outcomes with the Infinion 16 Lead
An analysis of 25 chronic pain patients who underwent an SCS trial showed that the Infinion 16 Lead delivered significant pain relief outcomes for those patients, including reduced pain intensity (p<0.0001) and improved pain relief (p<0.0001).
"The Infinion 16 is the only lead that provides 16 contacts that can be inserted through a single, small needle with just one lead placement," said Timothy Chafin , M.D., pain management specialist at Vidant Roanoke-Chowan Hospital in North Carolina and lead author of the study. "Added coverage of the spinal cord provides me with more options to manage my patients' chronic pain."
Reducing Lead Migration with the Clik Anchor: A Real-World Review
"Lead migration is the most common complication of spinal cord stimulation and may lead to additional surgery to revise lead placement," said Stephen Pyles , M.D., of the Florida Pain Clinic in Ocala, Florida. "In my clinical experience, the Clik Anchor reduces the potential for additional surgical procedures."
About the Clik Anchor
Lead migration is the most common complication of SCS. The Clik Anchor was designed to improve lead anchoring speed and consistency through an innovative locking system. Locking into place on the lead with a simple turn of a hex wrench, the Clik Anchor provides tactile and audible confirmation for physicians that the lead is secured.
About the Infinion 16 Percutaneous Lead
Spinal cord stimulator leads are designed to deliver electrical pulses from an implantable pulse generator to the spinal cord to mask pain signals to the brain. Until the Infinion 16 Percutaneous Lead, percutaneous leads offered a maximum of eight stimulating contacts. By providing twice the number of contacts as any previous percutaneous lead, the Infinion 16 Percutaneous Lead is designed to offer more coverage of the spinal cord for the management of chronic pain.
About Boston Scientific Neuromodulation
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, markets for our products, clinical trials and clinical outcomes, product performance and effects. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Lorie Fiber 310-623-0404 (mobile) Media Relations Weber Shandwick [email protected]
Steven Campanini 508-652-5740 (office) Media Relations Boston Scientific Corporation [email protected]
Sean Wirtjes 508-652-5305 (office) Investor Relations Boston Scientific Corporation [email protected]
SOURCE Boston Scientific Corporation